Table 3.
The infection sites of patients with IRH after intensive immunosuppressive therapy.
| Infection sites | Total (n = 433) |
Lupus nephritis (n = 376) |
ANCA glomerulonephritis (n = 57) |
p Value |
|---|---|---|---|---|
| Respiratory system, n (%) | 290 (67.0) | 247 (65.7) | 43 (75.4) | .191 |
| Skin and soft tissue, n (%) | 75 (17.3) | 69 (18.4) | 6 (10.5) | .205 |
| Digestive system n, (%) | 27 (6.2) | 20 (5.3) | 7 (12.3) | .066 |
| Urinary system, n (%) | 59 (13.6) | 56 (14.9) | 3 (5.3) | .077 |
| Central nervous system, n (%) | 2 (0.5) | 2 (0.5) | 0 | .452 |
| Blood, n (%) | 14 (3.2) | 13 (3.5) | 1 (1.8) | .464 |
| Others, n (%) | 7 (1.6) | 6 (1.6) | 1 (1.8) | .930 |
IRH: infection-related hospitalization.